Newborn affected by other maternal medication
ICD-10 P04.1 is a billable code used to indicate a diagnosis of newborn affected by other maternal medication.
P04.1 refers to newborns who are affected by maternal medications, particularly those substances that can be transmitted through the placenta or breast milk. This includes exposure to noxious substances such as illicit drugs, alcohol, and tobacco during pregnancy or breastfeeding. Maternal drug use can lead to a variety of neonatal complications, including withdrawal symptoms, growth restrictions, and developmental delays. Alcohol exposure can result in fetal alcohol spectrum disorders (FASD), while tobacco use is associated with low birth weight and respiratory issues. The clinical management of these newborns often requires a multidisciplinary approach, including neonatology, pediatrics, and social services, to address both immediate health concerns and long-term developmental support. Accurate coding is essential for appropriate treatment planning and resource allocation.
Detailed maternal substance use history, neonatal assessment of withdrawal symptoms, and developmental evaluations.
Newborns presenting with withdrawal symptoms in the NICU, requiring monitoring and supportive care.
Consideration of the timing and type of maternal substance exposure for accurate coding.
Ongoing developmental assessments and follow-up care plans for affected newborns.
Pediatric visits for developmental delays or behavioral issues stemming from prenatal exposure.
Awareness of the long-term implications of maternal substance use on child development.
Used when a newborn affected by maternal medication requires initial evaluation.
Document the newborn's clinical status and maternal history.
Neonatologists should ensure comprehensive assessments are performed.
Documentation must include a detailed maternal history of substance use, clinical assessments of the newborn, and any observed withdrawal symptoms or complications.
